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N.myc oncogene amplification in neuroblastoma has been found to be significantly associated with advanced 
stage disease and tumor progression. However, there is a lack of data on tumors, regarding the relationship 
between N-myc gene amplification and proliferation activity. Proliferating cell nuclear antigen (PCNA) is a 
proliferation-induced 36 kD nuclear protein that is the auxiliary component of DNA polymerase b. PCNA 
levels in tissues have been found to correlate with proliferative activity. We have examined PCNA levels in 
neuroblastomas in relation to N-myc gene amplification and tumor stage. Statistically, significantly higher 
levels of PCNA were observed in tumors with an amplified N-myc gene relative to tumors with a single gene 
copy. The highest levels of PCNA were observed in advanced stage tumors with an amplified N-myc gene. 
Treatment of neuroblastoma cells in culture with retinoic acid, which induces differentiation, resulted in a 
substantial decrease in PCNA. Our results suggest that PCNA levels may reflect differences in proliferative 
activity between neuroblastomas, related to stage of the disease and to N-myc gene copy number. 
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Introduction 
A large number of molecular events and factors 
responsible for progression of cells during the cell 
cycle have been defined [1]. PCNA was originally 
described as a nuclear antigen to which some 
patients with systemic lupus erythematosis develop 
autoantibodies [2-4]. In contrast to resting cells 
that synthesize very little PCNA, transformed cells 
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synthesize PCNA constitutively and in amounts 
proportional to the degree of transformation [5-7]. 
A polypeptide designated cyclin was independently 
found to be preferentially synthesized during the S 
phase and has been found to be identical to PCNA 
[5, 6, 8, 9]. In normal cells that have been induced 
to proliferate, for example following mitogen 
stimulation of resting peripheral blood lympho- 
cytes, PCNA expression increases from the late G1 
phase through the S phase of the cycle [5, 9]. 
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Exposure of exponentially growing cells to anti- 
sense oligodeoxynucleotides to PCNA resulted in 
complete suppression of DNA synthesis and mito- 
sis, indicating an important role for PCNA in cell 
proliferation [10]. Expression of PCNA is elevated 
in a wide range of abnormally proliferating cells, 
including carcinomas of the breast, colon, lung, 
kidney, stomach, skin, ovaries and testes [11]. 
PCNA positivity has been found to correlate with 
mitotic activity and tumor grade [11]. In chronic 
myeloid leukemia, PCNA expression is elevated 
during blast crisis [12]. We have previously studied 
PCNA expression in childhood acute leukemia and 
have observed differences in PCNA levels between 
lineage-related subtypes that have a different prog- 
nosis [13]. 
Neuroblastoma is a solid tumor of childhood 
which has a variable outcome related to stage and 
amplification of the N-myc oncogene [14-22]. To 
date, few data are available regarding the relation- 
ship between N-myc gene amplification and in 
vivo proliferative activity of tumors. In this study, 
we have examined the variability of PCNA 
expression in neuroblastoma in relation to tumor 
stage and N-myc gene copy number. Our findings 
indicate that higher PCNA levels occur in tumors 
with an amplified N-myc gene relative to tumors 
with a single N-myc gene, and in metastatic rela- 
tive to non-metastatic tumors. 
Materials and methods 
Tumors and cell lines 
Tumors were obtained from 40 newly diagnosed 
pediatric patients at the time of surgery, prior to 
chemotherapy, and represented all clinical stages 
of the disease, from localized (stage I) to meta- 
static disease (stage IV). Informed consent was 
obtained in all cases. These tumors were analysed 
previously for the expression of two other pro- 
liferation-related proteins, namely Op18 and 
p19/nm23 [23,24]. Of the 40 tumors studied for 
their content of PCNA, four belonged to the 
special group of infants with metastatic disease 
(stage IV-S), associated with a very good out- 
come, all of whom had a normal N-myc gene copy 
number. N-myc gene copy number was deter- 
mined as described previously [14]. Fifteen neuro- 
blastoma cell lines were also analysed for their 
PCNA content by two-dimensional (2-D) PAGE. 
Five cell lines had a non-amplified and 10 had an 
amplified N-myc gene (25-150 copies). All cell 
lines were derived from advanced stage tumors. 
The cell line KCNRP-9 was treated with retinoic 
acid as described previously [24-26]. 
2-D PAGE 
Samples of approximately 200/zg of tumor tissue 
were cut from larger size pieces and solubilized by 
addition of (per liter) 8 M urea, 20 ml of Nonidet 
P-40 surfactant, 20 ml of ampholytes (pH 3.5-10), 
20 ml of 2-mercaptoethanol, and 0.2 mM of phe- 
nylmethylsulfonyl fluoride in distilled deionized 
water. For neuroblastoma cell lines, 2 x 106 cells 
were similarly solubilized. Two-dimensional PAGE 
was performed as described previously [27]. In 
most cases 20-30 ~1 aliquots containing approxi- 
mately 70/.tg of protein were applied immediately 
onto isofocusing gels. First dimension gels con- 
tained 50 ml of ampholytes per liter (pH 3.5-9.0). 
Isofocusing was performed at 1200 V for 16 h and 
1500V for the last 2h.  Twenty gels were run 
simultaneously. For the second dimension separa- 
tion, an acrylamide gradient of 11.4-14.0 g/dl was 
used. Protein spots in gels were visualized using 
the silver-staining technique [28]. 
Quannfication of PCNA 
Spot detection and quantitation were performed as 
described previously [29]. Each gel was scanned in 
a 1024 x 1024 pixel format, giving 160/zm as the 
pixel width. The digitized images were assigned 
coded numbers and were analysed for the presence 
and quantity of PCNA, without knowledge of the 
sample to which a gel image correspond. PCNA 
was identified, based on its characteristic migration 
and position in relation to neighboring landmark 
spots that were present in all gels included in this 
study and that were recognizable to the analyst. 
The PCNA spot, as well as 20 other reference 
spots, were quantified by placing a cursor on each 
spot, on the graphics monitor, and typing in the 
name for the spot. The reference spots correspond 
to cellular proteins, most of which were 
identified recently by our group on the basis of 
sequencing information (manuscript in prepara- 
tion). The integrated intensity of each spot was 
measured in units of optical density x mm 2. Data 
on these spots were analysed using the Michigan 
Interactive Data Analysis System, a statistical soft- 
ware package. The 20 reference spots were used to 
adjust the PCNA spot-integrated intensity as 
described previously [29], to compensate for any 
variability in protein loading or staining between 
gels. For comparison of spot intensities between 
groups, ANOVAs, t-tests and calculation of corre- 
lation coefficients were used where appropriate. 
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Results 
We previously identified PCNA in 2-D gels on the 
basis of its molecular weight, pI, and its character- 
istic location relative to other  landmark proteins 
(Figure 1). The polypeptide spot that was pre- 
sumed to be PCNA increased substantially follow- 
ing phytohemagglutinin stimulation of peripheral 
blood lymphocytes. Its identity was further con- 
firmed by N-terminal sequencing which yielded the 
sequence K , F , E , A , R , L , V , Q , G , S , I , L , K  that uni- 
quely corresponded to PCNA [13]. In this study, 
the identity of PCNA in neuroblastoma-derived 
2-D P A G E  patterns was confirmed by Western 
blotting [30]. An antibody preparation to PCNA 
(19F4) reacted strongly and exclusively in 2-D gels 
of neuroblastoma tumors with the polypeptide pre- 
sumed to be PCNA. 
Differential expression of PCNA in relation to 
tumor stage and N-myc gene copy number 
Twenty-three neuroblastomas in which the N-myc 
gene occurred as a single copy were compared 
with 17 tumors in which the N-myc gene was 
amplified. A highly significant difference in PCNA 
levels was observed between tumors containing 
one N-myc gene copy and tumors with an ampli- 
fied N-myc gene (Figure2;  Table1 ;  mean inte- 
Figure l. Two-dimensional polypeptide pattern of a 
neuroblastoma tumor. PCNA is indicated along with two 
reference proteins (actin and Op18). 
grated in tens i t ies=0 .73  and 1.46, respectively, 
P =0.001) .  This difference in mean integrated 
intensity corresponds to a three-fold difference in 
protein amount  based on previous quantitative 
Figure 2. Enlarged 2-D PAGE pattern in the vicinity of PCNA in a neuroblastoma tumor tissue with one N-myc gene 
copy (A) and in tissue from a tumor with amplified N-myc (B). (Patients 7 and 28, respectively.) 
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Table 1. Patients with neuroblastomas as listed by N- 
myc gene copy number and stage. Relative PCNA 
values are provided for tumor tissue from each patient 
Patient Stage N-myc copy PCNA 
number 
1 1 1 0.64 
2 1 1 0.26 
3 1 1 0.11 
4 1 1 0.51 
5 2 1 0.34 
6 2 1 2.10 
7 2 1 0.68 
8 3 1 0.83 
9 3 1 0.28 
10 3 1 0.28 
11 3 1 0.47 
12 3 1 0.23 
13 3 1 0.64 
14 3 1 0.63 
15 4 1 0.92 
16 4 1 1.65 
17 4 1 0.80 
18 4 1 0.57 
19 4 1 1.06 
20 4S 1 0.46 
21 4S 1 1.70 
22 4S 1 0.90 
23 4S 1 0.80 
24 4 6-8 1.30 
25 3 100 2.83 
26 2 20 1.05 
27 3 50 0.86 
28 3 50 1.44 
29 4 60 0.51 
30 2 100 0.70 
31 2 125 0.46 
32 3 150 1.11 
33 3 150 1.70 
34 4 150 1.86 
35 3 200 1.52 
36 3 200 3.14 
37 4 200 2.69 
38 4 200 1.73 
39 3 200 0.63 
40 4 300 1.33 
analysis of proteins using 2-D P A G E  [29]. Most 
polypeptides observed in 2-D patterns of tumor 
tissue were also present in patterns of neuroblas- 
toma cell lines. However,  some polypeptides in the 
tissue patterns were absent from patterns of cul- 
tured neuroblastoma cells and were clearly derived 
from stromal tissue. They corresponded to major 
polypeptides observed in plasma and erythrocyte 
2-D gel patterns. However,  there was no signifi- 
cant relationship between the amount of PCNA 
and relative abundance of non-tumor cell proteins. 
Thus, the amount of PCNA observed in tumor 
tissue did not appear to vary in a manner related 
to variable amounts of stromal tissue. 
Significant quantitative differences in PCNA 
levels were observed between tumors, based on 
stage, without categorization based on N-myc gene 
copy number. The means for stages I - I V  were 
0.38, 0.89, 1.11 and 1.31, respectively (n = 4, 6, 15 
and 11; correlation coefficient, r = 0.36, P - - 0 . 0 1 ;  
Spearman's rho = 0.42, P =  0.012). As these 
results are confounded by variation in N-myc gene 
copy number,  variation in P C N A  expression with 
stage was examined separately in the group of 
tumors with a single N-myc gene copy and in the 
group with an amplified N-myc gene. In the for- 
mer, a significant difference in PCNA mean- 
integrated intensity was observed between non- 
metastatic (stages I, II and III) and metastatic 
tumors (stages IV and I V - S ;  mean intensities 0.57, 
n = 1 4 ,  vs 0.98, n = 9 ,  P = 0 . 0 5  by t-test). 
Interestingly in this group of N-myc = 1 there was 
no difference between stages IV and I V - S  
(respectively 1.00 and 0.97, n = 5 and 4). Among 
tumors with amplified N-myc gene, there was no 
difference in mean PCNA-integrated intensity 
between non-metastatic and metastatic stage tu- 
mors. For stage IV tumors, a higher mean level of 
PCNA was observed with N-myc gene amplifica- 
tion than with single gene copy tumors (mean 
= 1.00 for single gene copy and 1.57 for amplified 
gene copy). However,  the difference did not reach 
statistical significance (P  = 0.15). 
PCNA levels in neuroblastoma cell lines 
Fifteen neuroblastoma cell lines were analysed for 
their PCNA content. All neuroblastoma cell lines 
exhibited high levels of PCNA (Table 2). There 
was no significant difference between five cell lines 
derived from tumors with a single N-myc gene 
copy (mean = 2.54) and 10 cell lines derived from 
tumors with an amplified N-myc gene 
(mean = 2.78). It should be noted, however, that 
all cell lines were derived from advanced stage 
tumors. 
Neuroblastoma cell lines can be induced to dif- 
ferentiate with retinoic acid (RA) [24-26]. The 
steady-state level of N-myc protein has been 
shown to decrease following R A  treatment of cell 
lines in which the N-myc gene is amplified [25]. 
An  increase in the number of receptors for the 
nerve growth factor (NGF) was reported to be 
associated with neuroblastoma differentiation 
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Table 2. Neuroblastoma cell lines with N-myc gene copy 
number and PCNA-integrated intensity values listed for 
each. All cell lines were from advanced study tumors. 
No difference in PCNA mean intensity was noted 
between non-amplified and amplified tumor cell lines 
Cell line N-myc copy PCNA-integrated 
number intensity 
SK-N-AS 1 3.76 
SK-N-FI 1 3.59 
SK-N-RA 1 2.08 
LHN 1 2.39 
LA-N-6 1 0.908 
LAN-5 25 3.85 
SMS-KANR 25 1.95 
LA-N-1 50 3.97 
KCNR 75 1.04 
SK-N-BE1 100 2.44 
CHP-134 100 1.69 
MSN I00 3.99 
SK-N-BE2 150 2.64 
SMS-SAN 150 3.35 
SMS-KAN 150 2.84 
following R A  t rea tment  [31]. We therefore exa- 
mined the effect of R A  t rea tment  on P C N A  
expression using the neuroblas toma cell line 
KCNRP-9  which contains 75 copies of the N-myc 
gene. There  was a slight drop in P C N A  mean 
integrated intensity by day 2 relative to control 
cells t reated with ethanol alone (mean intensity 
1.74 vs 2.28, P = 0.10). By day 10 the difference 
between ret inoic-treated and control cells 
(Figure 3) was significant (0.86 and 2.29, 
P < 0.001). 
Discuss ion  
Neuroblas toma is a common  childhood tumor  
which originates in neural crest derived cells. 
Children with the tumor  present  with local, 
regional or metastat ic disease. In studies of neuro- 
blastoma tumors,  amplification of the N-myc 
oncogene has been found to be significantly associ- 
ated with advanced stage disease and rapid tumor  
progression [14-18,22] .  In this study, we have 
examined the expression of P C N A  in untreated 
neuroblas toma tumors,  in relation to N-myc gene 
copy number ,  to determine the relationship 
between N-myc amplification and tumor  proliferat- 
ive activity. Our  findings indicate that expression 
of P C N A  in neuroblas toma is elevated in tumors 
with an amplified N-myc gene, and that in the 
group with a single copy N-myc gene, tumors that 
belong to the metastat ic stages IV and I V - S  
exhibited higher levels than non-metastat ic  stage 
tumors.  P C N A  levels ranged f rom a mean  of 0.38 
for non-amplif ied N-myc gene stage I tumors,  to 
1.57 for stage IV tumors with an amplified N-myc 
gene. The mean level of  P C N A  in non-amplif ied 
stage I tumors approximates  the level we have 
observed previously in normal  resting lymphocytes 
[13], suggestive of low proliferative activity in 
these tumors.  The mean P C N A  level of 1.57 for 
amplified N-myc gene stage IV tumors approxi- 
mates  the mean observed for pre-B acute leukemia 
[13]. Established neuroblas toma cell lines, which 
are derived f rom advanced stage tumors and are 
believed to undergo selection as a result of culture 
conditions [14], display a markedly elevated P C N A  
level of 2.70 (S.D. 1.03), which approaches the 
Figure 3. Two-dimensional PAGE peptide patterns for the KCNRP-9 neuroblastoma cell line. (A) PCNA for cells 
treated with ethanol alone as a control for 10 days; (B) PCNA at a reduced level for cells treated with retinoic acid 
for 10 days. Relative PCNA spot intensity values for (A) and (B) are, respectively, 2.37 and 0.81. 
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level observed in T-ALL,  a subtype usually associ- 
ated with high proliferative activity and a high 
tumor load. While direct comparisons between 
PCNA levels in lymphoid cells and in neuroblas- 
toma are of limited use, the wide range of PCNA 
expression in neuroblastoma, approximating the 
range observed between resting lymphocytes and 
T-ALL,  suggests a wide range of proliferative 
activity in different tumors. 
To date, there have been limited studies of 
proliferation kinetics in neuroblastoma [32,33]. 
Mean generation times for undifferentiated tumors 
range from less than 13 h to 260 h, with potential 
tumor doubling time ranging from 20 to 415 h. 
[3H]Thymidine labeling indexes have been 
reported to vary between 3 and 28%, and growth 
fractions between 0.48 and 0.58. In neuroblas- 
toma, the duration of the cell cycle has been found 
to vary by a factor of up to 20, from 0.5 to 11 
days. The duration of DNA synthesis, the G2 
phase and mitosis were rather constant in a par- 
ticular case, whereas the G1 phase is a variable 
parameter  [32, 34]. In these studies the relation- 
ship between proliferation kinetics and N-rnyc 
gene copy number was not determined. In another  
study, tumors with an amplified N-myc gene were 
found to have a higher percentage of cells in S 
phase, though the relationship was not statistically 
significant and no definitive conclusions could be 
made (P  = 0.14) [35]. The PCNA data we have 
obtained, with statistically highly significant differ- 
ences between tumors with a single N-rnyc gene 
copy and tumors with an amplified N-myc 
oncogene, suggest differences in proliferative activ- 
ity in neuroblastoma related to the status of the 
N-myc gene. 
Cell cycle differences between neuroblastoma 
tumors could be related to differences in rate 
limiting factors that control progression of tumor 
cells through the cell cycle. Such differences have 
been implicated for certain tumors [34]. Control of 
the rate of proliferation of tumors may occur at 
the GI /S  interface, a phase during which PCNA 
synthesis peaks. Therefore ,  among neuroblastoma 
tumors, those exhibiting relatively high PCNA 
level may contain a greater number  of cells that 
can progress through the cell cycle. It is possible 
that increased N-myc protein level resulting from 
N-myc gene amplification or from prolonged N- 
myc mRNA or protein half-life [35, 36] may either 
increase expression of the PCNA gene directly or 
indirectly through intermediate factors that in turn 
regulate the expression of the PCNA gene. 
Retinoic acid or phorbol ester-induced maturation 
of neuroblastoma cells in culture substantially 
decreases N-myc mRNA [37] and proliferative 
activity. The decrease in PCNA levels which we 
have observed with RA treatment of KCNR 
neuroblastoma cells further suggests a link be- 
tween N-myc, PCNA protein levels and prolifera- 
tion. 
It is of interest that among tumors with a single 
N-myc gene copy, tumors that belong to stage IV 
and IV -S  display equivalent PCNA levels. While 
these tumors have a markedly different outcome, 
they share a high tumor load. It is likely therefore 
that PCNA levels directly reflect tumor prolifera- 
tive activity which in certain cases as in IV-S  
tumors may not be related to prognosis. We have 
previously reported that two other  cellular 
polypeptides, Op18 and p19/nm23, that are in- 
duced in proliferating cells, displayed differences 
in their levels between advanced stages III and IV 
and stages with a good prognosis including stage 
IV -S  [23, 24]. Several other  polypeptides observed 
in 2-D gels which have yet to be identified have 
exhibited variable expression in neuroblastoma. 
Sequencing studies of these polypeptides are curr- 
ently being undertaken. Detailed analysis of the 
extent of differential expression between neuro- 
blastoma tumors of polypeptides that play a role in 
cell proliferation is likely to improve our under- 
standing of the molecular basis of tumor hetero- 
geneity that may be responsible for a varied out- 
come in neuroblastoma. 
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